FRISC II

FRISC II
Name	FRISC II
Full name	Fragmin and Fast Revascularisation during InStability in Coronary disease II
Acronym	FRISC II
Phase	Clinical trial
Condition	Acute coronary syndromes
Intervention	Invasive strategy versus conservative strategy; antithrombotic therapy
Start date	1996
Completion date	2000
Primary outcome	Death or myocardial infarction
Sample size	~2,457
Countries	Sweden, Norway, Denmark, Finland

FRISC II FRISC II was a landmark randomized clinical trial that evaluated early invasive management compared with an initial conservative strategy in patients with unstable coronary syndromes. The trial informed practice guidelines across cardiology societies and influenced subsequent trials, registries, and policy decisions in cardiovascular care.

Background and Rationale

The trial arose amid debates in the 1990s involving institutions and figures such as European Society of Cardiology, American College of Cardiology, World Health Organization, National Institutes of Health, University of Gothenburg, Karolinska Institutet, Oulu University Hospital, Danderyd Hospital, Sahlgrenska University Hospital, and prominent investigators connected to trials like GUSTO, ISIS-2, TIMI IIIB, FRISC I, TACTICS-TIMI 18, PURSUIT, RITA-2, CURE, OPUS-TIMI 16, and PRISM-PLUS. Rising use of percutaneous coronary intervention at centers such as Rigshospitalet, Herlev University Hospital, Odense University Hospital, and St. Olavs Hospital encouraged testing whether routine early coronary angiography and revascularisation improved outcomes compared with selective invasive approaches endorsed by guideline committees from European Heart Journal authors and panels including contributors from Royal College of Physicians, American Heart Association, and British Cardiovascular Society.

Study Design and Methods

FRISC II employed a randomized, controlled, open-label design with blinded outcome adjudication, coordinated across Nordic centers including Sahlgrenska University Hospital, Karolinska University Hospital, Akershus University Hospital, and trial offices affiliated with University of Umeå and University of Copenhagen. Methods reflected standards from earlier multicenter trials like ISIS-2 and GUSTO and incorporated angiographic core labs similar to those used in MIRACLE and EVEREST. Statistical planning referenced techniques from researchers associated with Copenhagen University, University of Oxford, Harvard Medical School, and Stanford University who had published on interim analyses in journals such as The Lancet, New England Journal of Medicine, Journal of the American College of Cardiology, and Circulation.

Patient Population and Interventions

Enrolled patients presented with symptoms of unstable angina or non-ST-elevation myocardial infarction at participating centers including Danderyd Hospital, Helsinki University Hospital, Södersjukhuset, and Odense University Hospital. Eligibility criteria paralleled definitions used in TIMI studies and inclusion/exclusion frameworks from PURSUIT and CURE. Participants were randomized to an early invasive strategy with routine coronary angiography followed by percutaneous coronary intervention or coronary artery bypass grafting when indicated, or to a conservative/fail-safe strategy reserving angiography for refractory ischemia or recurrent events. Background pharmacotherapy included agents referenced in trials such as heparin protocols from GUSTO and adjunctive strategies similar to antiplatelet regimens tested in CURE and thrombolytic studies like ISIS-2.

Primary and Secondary Outcomes

The primary composite outcome was death or myocardial infarction at predefined time points, consistent with endpoints in TIMI and GUSTO programs. Secondary outcomes included recurrent ischemia, need for urgent revascularisation, quality-of-life metrics paralleling instruments used in trials led by European Heart Journal contributors, and resource-utilization endpoints comparable to analyses from RITA-2 and PRISM-PLUS.

Results and Statistical Analysis

FRISC II reported that an early invasive strategy reduced the composite of death or myocardial infarction compared with a conservative strategy, with absolute and relative risk reductions assessed using Kaplan–Meier estimates and Cox proportional hazards models. Analytic techniques echoed methods from New England Journal of Medicine reports of trials such as TIMI IIIB and TACTICS-TIMI 18, and subgroup analyses were stratified by biomarkers and clinical features similar to approaches in PURSUIT, CURE, and PRISM-PLUS. Findings influenced meta-analyses that pooled data with trials like TACTICS-TIMI 18, RITA-2, PURSUIT, and ICTUS to refine effect estimates.

Clinical Implications and Impact

FRISC II informed guideline revisions from bodies including European Society of Cardiology, American College of Cardiology, American Heart Association, and national societies in Sweden, Norway, Denmark, and Finland. The trial affected practice at centers such as Karolinska University Hospital, Rigshospitalet, Sahlgrenska University Hospital, and influenced quality metrics tracked by registries like Swedish Coronary Angiography and Angioplasty Registry and international efforts exemplified by GRACE and Euro Heart Survey. Health technology assessments and policy documents from agencies in United Kingdom, Denmark Health Authority, Swedish National Board of Health and Welfare, and Norwegian Directorate of Health considered FRISC II data when recommending pathways for unstable coronary syndromes.

Criticisms and Subsequent Research

Critiques addressed generalizability to populations treated with newer antiplatelet agents and high-sensitivity troponin assays, concerns also raised in later trials such as ICTUS, ACUITY, TRITON-TIMI 38, PLATO, MOVRAR, and registry analyses from GRACE and Euro Heart Survey. Methodological discussions referenced lessons from GUSTO, ISIS-2, TIMI programs, and randomized comparisons including TACTICS-TIMI 18 and PRISM-PLUS. Subsequent randomized trials, meta-analyses, and guideline updates continued to integrate FRISC II findings alongside data from CURE, PURSUIT, ICTUS, TACTICS-TIMI 18, ACUITY, PLATO, and population studies from Swedish Coronary Angiography and Angioplasty Registry to refine timing and selection for invasive strategies.

Category:Clinical trials in cardiology